A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Trial Profile

A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Talimogene laherparepvec (Primary)
  • Indications Breast cancer; Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 28 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 02 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 12 Apr 2018.
    • 06 Feb 2018 Planned End Date changed from 25 Apr 2021 to 13 May 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top